Market Research Report
Healthcare Contract Research Organization (CRO) Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-Clinical, Clinical), By Service, By Region, And Segment Forecasts, 2019 - 2025
|Published by||Grand View Research, Inc.||Product code||639957|
|Published||Content info||200 Pages
Delivery time: 2-3 business days
|Healthcare Contract Research Organization (CRO) Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-Clinical, Clinical), By Service, By Region, And Segment Forecasts, 2019 - 2025|
|Published: March 6, 2019||Content info: 200 Pages||
The global healthcare contract research organization (CRO) market size is expected to reach USD 54.7 billion by 2025, according to a new study by Grand View Research Inc. It is anticipated to expand at a CAGR of 6.6% during the forecast period. Increasing cost of drug development is expected to drive the growth. Drug maker and sponsor companies are under pressure to replace the revenue loss caused by generics, increasing patent expirations, number of partnerships to identify biologics, and growing R&D costs, which has made drug development more expensive and complex.
Regulatory framework for drug discovery and drug development is complex in various countries. Thus, an increasing need for expertise in different areas of drug development is driving the demand for outsourcing services. Drug companies are not only outsourcing production of medicines, but also clinical trials. With increasing privatization of clinical trials, there has been an increase in outsourcing of manufacturing processes to developing regions such as India, China, and Latin American countries.
China and India are projected to witness tremendous growth in near future, owing to their treatment naive patient pool coupled with high disease prevalence. Furthermore, genetically diverse population, highly qualified investigators, and well-equipped hospitals are other factors creating growth opportunities in India for global clinical trials market.
In addition, growing pressure on market players to follow stringent timelines has increased the demand for outsourcing of research activities. Even government organizations are outsourcing their clinical trial activities to CROs so that they can carry out the clinical trials with the required infrastructure, expertise, and minimize cost and timelines. In 2015, the Canadian Federal Budget made an investment of USD 1.33 billion for the Canada Foundation for Innovation (CFI).
In January 2016, Charles River Laboratories International, Inc. entered into a definitive agreement to acquire WIL Research for approximately USD 585 million. The acquisition is expected to strengthen Charles' ability to partner with global clients. The high R&D spending in oncology has also fueled the need for healthcare contract research outsourcing. Realizing this demand, France-based laboratory, XenTech increased its capacity of its animal care to 50% along with increasing collaborative research projects.
CROs are in a process of continuously improving their portfolio by integrating services with technology. This enables them to save more on time and deliver efficient and desired results to the clients. In June 2016, LSK Global Pharma Services Co., Ltd. expanded the use of Medidata Clinical Cloud by Medidata Clinical Solutions, Inc. Established in the year 2000, the company conducts clinical trials at both local and global scale. It utilizes Medidata's electronic data capture, unified randomization, medical coding solution, and trial management supply solution.
In addition to offering improved services, CROs are in the process of collaborating to promote their services at a global level. For instance, In June 2017, PAREXEL entered into a merger agreement with West Street Merger Sub, Inc., a wholly-owned subsidiary of West Street Parent, LLC. According to the merger agreement, PARAXEL will survive as a subsidiary of West Street Parent, LLC, in a transaction valued at approximately USD 5.5 billion.
In September 2017, Laboratory Corporation of America Holdings acquired Chiltern in a transaction worth USD 1.2 billion. Chiltern became a part of LabCorp's Covance Drug Development business unit.